PE20081751A1 - Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor - Google Patents

Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor

Info

Publication number
PE20081751A1
PE20081751A1 PE2008000265A PE2008000265A PE20081751A1 PE 20081751 A1 PE20081751 A1 PE 20081751A1 PE 2008000265 A PE2008000265 A PE 2008000265A PE 2008000265 A PE2008000265 A PE 2008000265A PE 20081751 A1 PE20081751 A1 PE 20081751A1
Authority
PE
Peru
Prior art keywords
antagonist
pharmaceutical composition
beta
ilmethyl
oxazole
Prior art date
Application number
PE2008000265A
Other languages
English (en)
Inventor
Katherine Wiley
Harry Finch
John Dixon
Original Assignee
Astrazeneca Ab
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081751(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Argenta Discovery Ltd filed Critical Astrazeneca Ab
Publication of PE20081751A1 publication Critical patent/PE20081751A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INGREDIENTE ACTIVO QUE ES UN ANTAGONISTA MUSCARINICO SELECCIONADO DE: SAL DE [2-((S)-CICLOHEXIL-HIDROXI-FENIL-METIL)-OXAZOL-5-ILMETIL]-DIMETIL-(3-FENOXI-PROPIL)-AMONIO; SAL DE [2-((R)-CICLOHEXIL-HIDROXI-FENIL-METIL)-OXAZOL-5-ILMETIL]-DIMETIL-(2-FENETILOXI-ETIL)-AMONIO; SAL DE [2-((R)-CICLOHEXIL-HIDROXI-FENIL-METIL)-OXAZOL-5-ILMETIL]-[2-(3,4-DICLORO-BENCILOXI)-ETIL]-DIMETIL-AMONIO; ENTRE OTROS; B) UN ANTAGONISTA DE BETHA2-ADRENORRECEPTOR PRINCIPALMENTE FORMOTEROL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2008000265A 2007-02-07 2008-02-06 Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor PE20081751A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0702385.6A GB0702385D0 (en) 2007-02-07 2007-02-07 New combination

Publications (1)

Publication Number Publication Date
PE20081751A1 true PE20081751A1 (es) 2008-12-27

Family

ID=37898913

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000265A PE20081751A1 (es) 2007-02-07 2008-02-06 Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor

Country Status (18)

Country Link
US (1) US20110046191A1 (es)
EP (1) EP2124941A1 (es)
JP (1) JP5337054B2 (es)
KR (1) KR20090114389A (es)
CN (2) CN101636390B (es)
AR (1) AR065202A1 (es)
AU (1) AU2008212649B2 (es)
BR (1) BRPI0806966A2 (es)
CA (1) CA2675718A1 (es)
CL (1) CL2008000380A1 (es)
GB (1) GB0702385D0 (es)
MX (1) MX2009008363A (es)
PE (1) PE20081751A1 (es)
RU (1) RU2460527C2 (es)
TW (1) TW200901986A (es)
UA (1) UA99604C2 (es)
WO (1) WO2008096126A1 (es)
ZA (1) ZA200905106B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
CN102089304A (zh) 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物
UY31920A (es) * 2008-06-20 2010-01-29 Astrazeneca Ab Nueva combinacion-408
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) * 2008-12-18 2009-01-28 Astrazeneca Ab New combination
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
MX2021003621A (es) 2018-09-28 2022-04-13 Karuna Therapeutics Inc Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico.
CN109896934A (zh) * 2019-03-08 2019-06-18 山东省药学科学院 一种高纯度2-苄氧基溴乙烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877470T2 (de) * 1987-09-10 1993-06-24 Merck Sharp & Dohme Oxazole und thiazole zur behandlung seniler demenz.
FR2675142B1 (fr) * 1991-04-10 1993-06-25 Roussel Uclaf Nouveaux derives de l'acide alpha-methylene 4-[(phenoxy) methyl] 5-thiazolacetique, leur procede de preparation et les intermediaires de ce procede et leur application a titre de fongicides.
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists
US6242448B1 (en) * 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
SE9902935D0 (sv) * 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
JP2005539046A (ja) * 2002-08-29 2005-12-22 シプラ・リミテッド 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
US7332175B2 (en) * 2003-05-27 2008-02-19 Boehringer Ingelheim International Gmbh Long-acting drug combinations for the treatment of respiratory complaints
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7745621B2 (en) * 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
WO2008017827A2 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
WO2008096093A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses

Also Published As

Publication number Publication date
AR065202A1 (es) 2009-05-20
CN101678005A (zh) 2010-03-24
KR20090114389A (ko) 2009-11-03
GB0702385D0 (en) 2007-03-21
WO2008096126A1 (en) 2008-08-14
RU2009133261A (ru) 2011-03-20
JP5337054B2 (ja) 2013-11-06
JP2010518059A (ja) 2010-05-27
AU2008212649B2 (en) 2011-05-19
TW200901986A (en) 2009-01-16
CN101678005B (zh) 2012-10-31
AU2008212649A1 (en) 2008-08-14
ZA200905106B (en) 2010-05-26
CL2008000380A1 (es) 2008-08-18
EP2124941A1 (en) 2009-12-02
MX2009008363A (es) 2009-08-20
US20110046191A1 (en) 2011-02-24
CN101636390B (zh) 2013-06-12
UA99604C2 (ru) 2012-09-10
CN101636390A (zh) 2010-01-27
RU2460527C2 (ru) 2012-09-10
BRPI0806966A2 (pt) 2014-04-08
CA2675718A1 (en) 2008-07-14

Similar Documents

Publication Publication Date Title
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2010222367A5 (es)
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
ATE534378T1 (de) Titrierung von tapentadol
ECSP088240A (es) Composición de trazodona para administración una vez por día
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2012002423A1 (es) Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil.
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
BRPI0813926A2 (pt) Utilização de uma substância, composição e métodos de triagem de princípios ativos que inibem a formação dos ages e de cuidado cosmético.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.

Legal Events

Date Code Title Description
FD Application declared void or lapsed